New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show

(MedPage Today) -- Use of the anti-CD19 CAR T-cell therapy obecabtagene autoleucel (obe-cel; Aucatzyl) resulted in durable remissions among patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), according to results from...